Evidence map›Paper›PMID 37283940›Full record

ArticleInfection and drug resistance2023

Microbiological Investigations of Fine Needle Aspirates from Newly Suspected and Previously Treated Tubercular Lymphadenitis Patients.

Abay Atnafu, Liya Wassie, Melaku Tilahun, Selfu Girma, Yohannes Zenebe, Muluye Abebe Beyene, Ashenafi Alemu, Emnet Fisseha, Haymanot Agze, Tigist Desta and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and drug resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Abay AtnafuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0001-7594-4004
Liya WassieArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Melaku Tilahun *Armauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-3101-3926
Selfu GirmaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-1866-0950
Yohannes ZenebeDepartment of Medical Laboratory Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia.
Muluye Abebe BeyeneArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Ashenafi AlemuArmauer Hansen Research Institute, Addis Ababa, Ethiopia.ORCID 0000-0002-9333-635X
Emnet FissehaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Haymanot AgzeArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Tigist DestaArmauer Hansen Research Institute, Addis Ababa, Ethiopia.
Kassu Desta *Department of Medical Laboratory Sciences, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0003-2906-1141
Kidist Bobosha *Armauer Hansen Research Institute, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Extrapulmonary tuberculosis (EPTB), particularly tubercular lymphadenitis (TBLN), remains to pose a huge public health problem in Ethiopia. A significant number of TBLN patients who completed a full course anti-TB treatment regimen were reported to have enlarged lymph nodes and other TB-like clinical presentations. This could either be from a paradoxical reaction or microbiological relapse, possibly due to mono/multi-drug resistance. Objective: To investigate the rate of mono and multidrug resistance patterns of Methods: A cross-sectional study was conducted on 126 TBLN-suspected and previously treated patients between March and September 2022. Data were analyzed using SPSS (Version 26.0). Descriptive statistics were used to determine the frequency, percentage, sensitivity, specificity, and positive and negative predictive values. The level of agreement was determined using Cohen's kappa and a Chi-square test was used to measure the association between risk factors and laboratory test outcomes. A Results: Conclusion: The emergence of drug resistant (DR) TB seems to not just be limited to pulmonary form but also to TBLN. In this study we observed a considerable number of microbiologically confirmed relapses among previously treated cases, possibly indicating the need for confirmation of drug resistance using rapid molecular methods or phenotypical methods during treatment follow up.

Indexed as

drug sensitivity testingDSTFNArelapsetubercular lymphadenitis

Identifiers

PMID37283940
PMCPMC10241182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.